MDGEF (Medigene AG) GF Value Rank: 2 (As of Jul. 20, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGEF Medigene AG MDGEF
12 GF Score
Price $2.59
View Full Analysis

What is Medigene AG GF Value Rank?

Medigene AG MDGEF 12 GF Value Rank is 2 as of Jul. 20, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates MDGEF with a GF Score™ of 12/100.

Medigene AG has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Medigene AG GF Value Rank Related Terms


MDGEF vs VRTX, REGN, ALNY: GF Value Rank Comparison

For the Biotechnology subindustry, Medigene AG's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigene AG GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Medigene AG's GF Value Rank falls into.


MDGEF
12GF Score
Medigene AG MDGEF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Medigene AG (MDGEF) has a GF Value Rank of 2 as of Jul. 20, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Medigene AG and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, Medigene AG's GF Value Rank has ranged from 1.00 to 10.00.
Is Medigene AG's GF Value Rank too high?
Medigene AG's current GF Value Rank of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's GF Value Rank compare to VRTX and REGN?
Medigene AG's GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Medigene AG's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Medigene AG and its competitors. Medigene AG's current GF Value Rank is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (MDGEF) has a current GF Value Rank of 2. The current GF Value Rank is 2, which is 33% below median its 10-year median of 3.00. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Medigene AG (MDGEF), the current GF Value Rank is 2 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for MDGEF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price